Gene · 340267
COL28A1: collagen type XXVIII alpha 1 chain
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. COL28A1: collagen type XXVIII alpha 1 chain. Genes, record 340267. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/340267
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q2UY09 | Collagen alpha-1(XXVIII) chain | 1,125 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents22
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 11665 | Q2UY09 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 12300 | Q2UY09 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 3284 | Q2UY09 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5949 | Q2UY09 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5949 | Q2UY09 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 12300 | Q2UY09 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 11665 | Q2UY09 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 3284 | Q2UY09 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 3284 | Q2UY09 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 3291 | Q2UY09 | Espacenet |
1 to 10 of 22
See all 22 patentsDrugs2
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
Trials66
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06169319 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | ClinicalTrials.gov | |
| NCT06151197 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE3 | ClinicalTrials.gov | |
| NCT06065436 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ClinicalTrials.gov | ||
| NCT05646602 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ClinicalTrials.gov | ||
| NCT05254457 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE3 | ClinicalTrials.gov | |
| NCT05152173 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | ClinicalTrials.gov | |
| NCT04874870 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE3 | ClinicalTrials.gov | |
| NCT04680156 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ClinicalTrials.gov | ||
| NCT04496167 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | 2023-09-13 | ClinicalTrials.gov |
| NCT04236635 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | PHASE2 | 2022-04-12 | ClinicalTrials.gov |
1 to 10 of 66
See all 66 trialsNIH grants129
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | COL28A1 papers | Newest fiscal year |
|---|---|---|---|
| I01BX003056 | Sirtuins in Lung Aging and Fibrosis | 1 | 2025 |
| P20GM103408 | Idaho INBRE Program | 1 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 1 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 1 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 1 | 2025 |
| P50CA136393 | Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancer | 1 | 2025 |
| P51OD011132 | Emory National Primate Research Center | 1 | 2025 |
| R01ES027778 | Mechanism for arsenic induced carcinogenesis | 1 | 2025 |
| R01GM121907 | Genomic basis of phenotypic variability of complex disorders | 1 | 2025 |
| R35GM128855 | Spindle Assembly Checkpoint Silencing | 1 | 2025 |
1 to 10 of 129Source NIH's project files
See all 129 nih grantsPapers124
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Urinary proteomic signature of exercise intolerance in patients at risk of heart failure: evidence from the HOMAGE trial. | EBioMedicine | 2026 | 42531722 | PubTator, text mining | PubMed |
| Development of Intervertebral Disc Organoids through Directed Differentiation of Mesenchymal Stem Cells and Hierarchical 3D Printing. | ACS Nano | 2026 | 41849687 | PubTator, text mining | PubMed |
| Integrative Spatial Transcriptomics and Immunoinformatics for Prognostic Multi-Epitope Vaccine Construct Prediction Against Synovial Sarcoma. | Pharmaceuticals (Basel) | 2026 | 41754822 | PubTator, text mining | PubMed |
| Temporal Transcriptomics Leads From Discovery to in Vivo Validation: COL4A3/COL4A6/ COL4A5 and ITGA8 as Novel Arthrofibrosis Biomarkers in Post-traumatic Joint Contracture. | Dose Response | 2026 | 41743075 | PubTator, text mining | PubMed |
| Specific non-myogenic mesenchymal cells contribute to rotator cuff tear myosteatosis and fibrosis revealing novel therapeutic options. | bioRxiv | 2026 | 41727035 | PubTator, text mining | PubMed |
| Plasma Proteome Signature for Leukocyte Telomere Length and Its Link to Abdominal Aortic Aneurysm. | J Cell Mol Med | 2026 | 41677031 | PubTator, text mining | PubMed |
| Integrated fetal testicular transcriptomic and epigenomic profiles during maternal nutrient restriction with dietary melatonin intervention. | J Anim Sci | 2026 | 41514165 | PubTator, text mining | PubMed |
| Exploring socio-economic, biochemical, and genetic factors influencing thyroid status in Indian school-going adolescents. | J Hum Genet | 2026 | 41249461 | PubTator, text mining | PubMed |
| Cancer-Associated Fibroblast-Centric Risk Model Predicts Immunotherapy Resistance in Pancreatic Cancer and Reveals PLOD2 as a Key Stromal Therapeutic Target. | Front Biosci (Landmark Ed) | 2025 | 41504058 | PubTator, text mining | PubMed |
| NOTCH gene pattern predicts prognosis, immune infiltration, and drug response in Head and Neck squamous cell carcinoma. | J Stomatol Oral Maxillofac Surg | 2025 | 41022354 | PubTator, text mining | PubMed |
1 to 10 of 124
See all 124 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/340267
GET https://conductscience.org/api/genes/v1/340267/patents?page=2